The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

The US Food and Drug Administration (FDA) has approved a label expansion for Novartis’s Kisqali (ribociclib), allowing it to be used as an add-on therapy in early breast cancer patients. The therapy ...

The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor as adjuvant treatment for adults with hormone receptor (HR)-positive, ...

A drug called ribociclib, currently used to treat breast cancer, could slow the progression of certain pediatric high-grade gliomas, an aggressive type of childhood brain cancer, a new study has ...

Ribociclib (brand name Kisqali) is a CDK4/6 inhibitor, a type of drug that targets specific enzymes — including the protein CDK6 — to stop cancer cells from growing. In the study, which was ...

In part 2 of this interview, Joseph Biggio, MD, system chair and service line leader for women's services and system chair for maternal fetal medicine at Ochsner Health, discusses some of the main ...

Aug. 31 (UPI) --Three dairies in central California have tested positive for avian flu, the first time the virus has been discovered in the state after spreading across the United States since March.

A drug already available on the NHS to treat breast cancer may also slow the growth of a rare and aggressive childhood brain tumour and prolong life, early research has shown. Scientists have ...

A drug already available on the NHS to treat breast cancer may also slow the growth of a rare and aggressive childhood brain tumour and prolong life, early research has shown. Scientists have found ...